Disease Site Committees
The NCI requires that each Cancer Center have a Protocol Review and Monitoring System (PRMS) to assess scientific merit and feasibility of all protocols studying subjects diagnosed with, or at risk for, cancer conducted at the Center and to monitor for accrual and scientific relevance; NCI looks for centralized oversight across the Center.
While the centralized oversight is provided by the Protocol Review Committee (PRC), the Helen Diller Family Comprehensive Cancer Center provides for additional disease-specific input via the various Disease Site Committees. These Disease Site Committees are charged with the contextual review, feasibility assessment and prioritization of each new concept and protocol as it relates to the patient populations and research focus of each Disease Site Committee. They consider relevant clinical programs, programmatic goals, expertise, and research interests in assessing both concepts and protocols. A protocol cannot move forward for review by the Protocol Review Committee (PRC) unless it has full approval from at least one Disease Site Committee.
All studies reviewed by a Disease Site Committee will be subject to:
Multiple Disease Site Committees exist covering all disease areas, including one for supportive care and one for early phase trials.
> for Disease Site Committee review process policies see ITR Policies
This unit is supported by a National Cancer Institute Cancer Center Support Grant (5P30CA082103). Any publications related to work done by this core should reference grant number 5P30CA082103 and must include a PMCID as required by the NIH. For complete instructions on how to acknowledge funding sources, please see http://grants.nih.gov/grants/acknow.htm. For more information on how to obtain a PMCID, please see http://publicaccess.nih.gov/submit_process.htm.
For more information on the CCSG, please contact Kate Shumate at firstname.lastname@example.org.